Wyeth

Jeffrey Scott Condon

Frank Eldridge Lovering

Albert Jean Robichaud

Michael Sotirios Malamas

Jeremy Ian Levin

Yang-I Lin

Jerauld S Skotnicki

Derek Cecil Cole

Ping Zhou

John W Ellingboe

William Floyd Fobare

Eric Steven Manas

William Ronald Solvibile

Joseph Raymond Stock

William Jay Moore

Lee Dalton Jennings

Koi Morris

George Diamantidis

Zhong Li

Kaapjoo Park

Weiheng Wang

Junjun Wu

Mohani Nirmala Sukhdeo

The present invention provides an amino-pyridine compound of formula I  The present invention also provides methods for the use thereof to inhibit &#x3b2;-secretase (BACE) and treat &#x3b2;-amyloid deposits and neurofibrillary tangles.

Amino-pyridines as inhibitors of &#x3b2;-secretase

This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-&#x3b1;, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.

Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase

The present invention provides an azolylacylquanidine compound of formula I  The present invention also provides methods for the use thereof to inhibit &#x3b2;-secretase (BACE) and treat &#x3b2;-amyloid deposits and neurofibrillary tangles.

Azolylacylguanidines as &#x3b2;-secretase inhibitors

Growing community of inventors

Cambridge, MA, United States of America

Jeffrey Scott Condon